Careers  |  Sign In  |  Register

Latest in Pathology & Lab Medicine

Recent data from an Agios leukemia drug trial has shown improved success in treating leukemia, according to an article from Reuters. Forty percent of the 158 patients responded to the treatment and nearly half of those who responded to the treatment saw no more cancer in the bone marrow and normal blood cell...
The common gastric reflux drugs classified as proton pump inhibitors (P.P.I.’s) have been found to increase one’s risk for a heart attack in a study of nearly three million individuals, according to The New York Times. Previous studies found that P.P.I.’s interacted negatively with a commonly...
According to Reuters, Ibrance, a breast cancer drug from Pfizer is currently in Phase III clinical trials of a new drug. The drug is designed to treat the most common type of breast cancer, estrogen-receptor positive, human epidermal growth factor receptor 2-negative. Ibrance has been shown to increase the...